Keep the quality high: the benefits of lot testing for the quality control of malaria rapid diagnostic tests.
Diagnostics
Lot testing
Malaria
Post-market surveillance
Quality control
Rapid diagnostic test
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
13 Jul 2020
13 Jul 2020
Historique:
received:
05
03
2020
accepted:
07
07
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
3
3
2021
Statut:
epublish
Résumé
The production and use of malaria rapid diagnostic tests (RDTs) has risen dramatically over the past 20 years. In view of weak or non-existing in vitro diagnostics (IVD) regulations and post-marketing surveillance (PMS) systems in malaria endemic countries, the World Health Organization, later joined by the Foundation for Innovative New Diagnostics, established an independent, centralized performance evaluation and Lot Testing (LT) programme to safeguard against poor quality of RDTs being distributed through the public health sector of malaria endemic countries. RDT performances and manufacturer quality management systems have evolved over the past decade raising questions about the future need for a centralized LT programme. Between 2007 and 2017, 6056 lots have been evaluated, representing approximately 1.6 Billion RDTs. A total of 69 lots (1.1%) failed the quality control. Of these failures, 26 were detected at receipt of the RDT lot in the LT laboratory, representing an estimated 7.9 million poor quality RDTs, and LT requesters were advised that RDTs were not of sufficient quality for use in patient management. Forty-three were detected after long-term storage in the laboratory, of which 24 (56%) were found to be due to a major issue with insufficient buffer volume in single use buffer vials, others predominantly showing loss of sensitivity. The annual cost of running the programme, based on expenses recorded in years 2014-2016, an estimated volume of 700 lots per year and including replenishment of quality control samples, was estimated at US$ 178,500 ($US 255 per lot tested). Despite the clear benefits of the centralized LT programme and its low cost compared with the potential costs of each country establishing its own PMS system for RDTs, funding concerns have made its future beyond 2020 uncertain. In order to manage the risks of misdiagnosis due to low quality RDTs, and to ensure the continued safety and reliability of malaria case management, there is a need to ensure that an effective and implementable approach to RDT quality control continues to be available to programmes in endemic countries.
Sections du résumé
BACKGROUND
BACKGROUND
The production and use of malaria rapid diagnostic tests (RDTs) has risen dramatically over the past 20 years. In view of weak or non-existing in vitro diagnostics (IVD) regulations and post-marketing surveillance (PMS) systems in malaria endemic countries, the World Health Organization, later joined by the Foundation for Innovative New Diagnostics, established an independent, centralized performance evaluation and Lot Testing (LT) programme to safeguard against poor quality of RDTs being distributed through the public health sector of malaria endemic countries. RDT performances and manufacturer quality management systems have evolved over the past decade raising questions about the future need for a centralized LT programme.
RESULTS
RESULTS
Between 2007 and 2017, 6056 lots have been evaluated, representing approximately 1.6 Billion RDTs. A total of 69 lots (1.1%) failed the quality control. Of these failures, 26 were detected at receipt of the RDT lot in the LT laboratory, representing an estimated 7.9 million poor quality RDTs, and LT requesters were advised that RDTs were not of sufficient quality for use in patient management. Forty-three were detected after long-term storage in the laboratory, of which 24 (56%) were found to be due to a major issue with insufficient buffer volume in single use buffer vials, others predominantly showing loss of sensitivity. The annual cost of running the programme, based on expenses recorded in years 2014-2016, an estimated volume of 700 lots per year and including replenishment of quality control samples, was estimated at US$ 178,500 ($US 255 per lot tested).
CONCLUSIONS
CONCLUSIONS
Despite the clear benefits of the centralized LT programme and its low cost compared with the potential costs of each country establishing its own PMS system for RDTs, funding concerns have made its future beyond 2020 uncertain. In order to manage the risks of misdiagnosis due to low quality RDTs, and to ensure the continued safety and reliability of malaria case management, there is a need to ensure that an effective and implementable approach to RDT quality control continues to be available to programmes in endemic countries.
Identifiants
pubmed: 32660630
doi: 10.1186/s12936-020-03324-3
pii: 10.1186/s12936-020-03324-3
pmc: PMC7359453
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Nat Rev Microbiol. 2006 Sep;4(9):682-95
pubmed: 16912713
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):119-27
pubmed: 18165483
BMC Health Serv Res. 2014 Oct 31;14:524
pubmed: 25366990
Malar J. 2008 Aug 22;7:160
pubmed: 18718028
Afr J Lab Med. 2014 Apr 04;3(1):123
pubmed: 29043177
Malar J. 2019 Dec 2;18(1):387
pubmed: 31791354
Malar J. 2017 May 15;16(1):196
pubmed: 28506275
Emerg Infect Dis. 2018 Mar;24(3):462-470
pubmed: 29460730
J Med Microbiol. 2013 Oct;62(Pt 10):1491-1505
pubmed: 24048274
Malar J. 2017 Apr 20;16(1):160
pubmed: 28427428